We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Muscle Stem Cells Treat Urinary Incontinence Long Term

By Biotechdaily staff writers
Posted on 04 Jun 2007
Women with stress urinary incontinence (SUI) treated using muscle-derived stem cell injections to strengthen their sphincter muscles experienced long-term improvements in their condition, according to new research.

A study led by researchers at the University of Pittsburgh School of Medicine (PA, USA) and Sunnybrook Health Sciences Centre (Toronto, Canada) tracked patients for more than one year, suggesting that the approach is safe, improves patients' quality of life, and may be an effective treatment for SUI. More...


"This clinical trial is extremely encouraging, given that 13 million people in the United States, most of them women, cope with stress urinary incontinence,” said Michael B. Chancellor, M.D., the study's senior investigator and professor of urology and gynecology at the University of Pittsburgh School of Medicine. "We're demonstrating for the first time that we may be able to offer people with SUI a long-term and minimally invasive treatment option.”

Earlier research in animal models of SUI completed at the University of Pittsburgh School of Medicine demonstrated that injecting stem cells into the urethral muscles increases leak-point pressure, leading to the restoration of the deficient muscles. The results of these studies formed the foundation for the clinical trial.

"The technique to achieve optimal efficacy is evolving, but we are pleased with what this study has shown,” added principal investigator Lesley Carr, M.D., urologist at Sunnybrook Health Sciences Centre and assistant professor at the University of Toronto. "We now have preliminary evidence that stem cells are safe to use and appear to improve female stress urinary incontinence.”

In the study, Dr. Carr and colleagues obtained biopsies of skeletal muscle tissue from eight female patients, and isolated and expanded the stem cells from the tissue in culture. In an outpatient setting, the patients then received injections of the muscle-derived stem cells into the area surrounding the urethra. Each patient received an equal dose of stem cell injections using three different injection techniques--a transurethral injection with either an 8-mm or 10-mm needle or a periurethral injection.

Five of the eight women who participated in the study reported improvement in bladder control and quality of life with no serious short- or long-term adverse effects one year after the initial treatment. These improvements were associated with both the 10-mm needle injections and the periurethral injections, which allowed the investigators to deliver the stem cells close to the damaged sphincter muscle. The 8-mm needle was not able to deliver the muscle stem cells deep enough into the tissue to reach the sphincter.

A multi-center study in Canada and a study in the United States are currently underway and will allow researchers to determine the optimal dose of muscle stem cells needed to effectively treat SUI.

Women with SUI involuntarily leak urine during activities that put pressure on the bladder, such as running, coughing, sneezing, or laughing. Stress incontinence is caused by childbirth, menopause, or pelvic surgery and is most frequently diagnosed in women during middle age.

The findings were recently presented at the Tissue Engineering and Regenerative Medicine in Urology briefing at the annual meeting of the American Urological Association (AUA) in San Diego, CA, USA.


Related Links:
University of Pittsburgh School of Medicine
Sunnybrook Health Sciences Center

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.